<DOC>
	<DOCNO>NCT00654108</DOCNO>
	<brief_summary>Enterotoxigenic Escherichia ( E. ) coli ( ETEC ) bacteria main cause traveler 's diarrhea significant pathogens affect child elderly individual develop country . The purpose study determine safety ETEC-Cholera vaccine body 's ability protect ETEC cholera infection receive vaccine . The study enroll total 64 healthy volunteer , 18 45 year old Cincinnati Children 's Hospital . The study provide increase dos vaccine placebo ( inactive substance ) 4 group consist 16 participant . Participants remain inpatient unit observation 11 day . All subject treat Cipro , antibiotic , 5 day . Study procedures include : blood sample , vital sign , physical examination , stool sample . Volunteers involve study 8 month include telephone contact .</brief_summary>
	<brief_title>Safety Immunogenicity Peru-15-pCTB Healthy Adult Subjects</brief_title>
	<detailed_description>Enterotoxigenic Escherichia coli ( ETEC ) principal single cause traveler 's diarrhea significant pathogen affect child elderly individual develop country . ETEC infection result approximately 600 million total case diarrhea worldwide annually , estimate 280 million case 400,000 death child le 5 year age . The propose study randomize , double-blind , placebo control , dose-escalation , inpatient Phase I study determine safety immunogenicity single oral dose combine live , attenuated , enterotoxigenic Escherichia coli ( ETEC ) -cholera vaccine ( Peru-15 pCTB ) . A total 64 healthy subject , 18 45 year old enrol study . Subject participation duration 8 month . Sequential cohort 16 eligible subject randomize 3:1 ratio receive assign dose ETEC-cholera vaccine placebo ( bicarbonate buffer ) , respectively . The first dose level cohort ( 1x10^7 colony form unit ) divide 2 group . Initially , 4 subject enrol , treat , observed ensure tolerability dose level Day 28 . In absence stopping rule , enrollment dose proceed remain 12 subject cohort . Thereafter , dose escalation subject enrollment proceed step-wise fashion . A Safety Monitoring Committee convene study , review available safety data Day 28 post-vaccination visit cohort prior make recommendation Sponsor advancement next dose level . The study conduct Cincinnati Children 's Hospital . The primary objective study assess safety combine ETEC-cholera vaccine [ Peru-15-pCTB ( Cholera toxin B-subunit ) ] administer single oral dose range dose healthy adult subject compare placebo day 28 post-vaccination . The secondary objective : assess long-term safety follow-up immunization Month 6 post vaccination ; evaluate immunogenicity single oral dose ETEC-cholera vaccine range dose healthy adult subject ; evaluate shed profile ETEC-cholera vaccine organisms stool period 7 day .</detailed_description>
	<mesh_term>Escherichia coli Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Ciprofloxacin</mesh_term>
	<criteria>Male female age 1845 , inclusive . Healthy judge Principal Investigator ( PI ) determine medical history , physical examination , vital sign , screen laboratory , medication history . Capable understanding , consent comply entire study protocol include inpatient period . Female subject must nonchildbearing potential , childbearing potential ( determined investigator ) must practice abstinence use effective license method birth control ( e.g. , oral contraceptive ; diaphragm condom combination contraceptive jelly , cream , foam ; intrauterine contraceptive device , DepoProvera ; skin patch ; vaginal ring cervical cap ) 30 day prior vaccination must agree continue precaution study 30 day Day 28 study visit . Male subject must agree father child study 90 day Day 0 study visit . Provide voluntary write informed consent attain least 70 % examination study first attempt . Have normal screen laboratory serum glutamic pyruvic transaminase ( SGPT ) alanine aminotransferase ( ALT ) , creatinine , sodium , potassium , total white blood count ( WBC ) , hemoglobin , neutrophil , lymphocyte , platelet , urine protein , urine glucose urine red blood cell ( RBC ) . Women pregnant lactate positive serum pregnancy test screen upon admission inpatient facility . Subjects immunocompromised immunodeficient , prior malignancy ( exception : history basal cell squamous cell carcinoma remission without treatment 5 year prior study entry ) . History clinically significant chronic illness condition require chronic medication therapy . History malabsorption maldigestion disorder ( e.g. , celiac sprue ) , major gastrointestinal ( GI ) surgery , chronic GI disorder would interfere study investigational product . Any current past use immunosuppressive medication include inhaled steroid ( e.g. , asthma ) within 6 month screen . Recent ( e.g. , within 5 year ) history travel cholera Enterotoxigenic Escherichia coli ( ETEC ) endemic area , raise cholera ETEC endemic area history raise child endemic area cholera ETEC . Individuals may work Vibrio ( V ) cholerae ETEC laboratory also exclude . Vaccination infection cholera E. coli , participation clinical trial use cholera ETEC vaccine organisms time . History drug alcohol abuse time last 6 month . Presence HIV antibody , hepatitis C antibody , positive hepatitis B surface antigen . Clinically abnormal screen electrocardiogram ( ECG ) define pathologic Q wave significant STT wave change ; criterion leave ventricular hypertrophy ; nonsinus rhythm exclude isolated premature atrial contraction . Presence bacterial parasitic pathogen stool culture screen stool examination . IgA ( immunoglobulin ) deficiency . A change subject 's normal stool pattern within 3 month screen visit . A normal stool pattern define 3 21 stool per week . Any known allergy sensitivity Ciprofloxacin . Have know allergy component vaccine [ M9 minimal salt , glycerin , dextrose anhydrous , sodium chloride , peptone ( vegetable ) acid hydrolysate , magnesium sulfate heptahydrate , aspartame ] placebo/bicarbonate buffer ( water , sodium bicarbonate , ascorbic acid , aspartame ) . Any medical illness require new prescription medication hospitalization screen period temperature great equal 38.0 degree Celsius 2 week prior investigational product administration ( Day 0 ) . Administration vaccine , license investigational , investigational product within 30 day investigational product administration ( Day 0 ) plan participation another investigational trial study . Use antibiotic within 7 day investigational product administration ( Day 0 ) . Use laxatives hard infrequent stool one time month 3 month prior enrollment . Use H2 receptor antagonist ( e.g. , Tagamet® , Zantac® , Pepcid® ) , proton pump inhibitor ( e.g. , Prilosec® counter ( OTC ) , Protonix® , Prevacid® ) , prescription acid suppression medication OTC antacid within 72 hour investigational product administration . Use prescription OTC medication contain acetaminophen , aspirin , ibuprofen , nonsteroidal antiinflammatory drug within 48 hour prior investigational product administration . Employment commercial food handler , day care worker , health care worker involve direct patient contact . Subjects child less 2 year old home household contact immunocompromised , pregnant breastfeeding . Any condition responsibility , medical , psychiatric , social condition occupational responsibility , judgment investigator , would interfere serve contraindication subject 's participation protocol assessment investigational product . Subjects unwilling unable cease smoke duration inpatient stay . Subjects unable pas test describe cholera ETEC diarrhea explain requirement clinical trial . Subjects must score minimum 70 percent upon first attempt . Subjects exclude screen laboratory test result fall outside laboratory normal ; however , transaminase level [ alanine aminotransferase ( ALT ) ] creatinine level ( Cr ) low limit `` normal '' exclusion criterion . Subjects Phenylketonuria ( PKU ) exclude investigational product ( vaccine ) bicarbonate buffer contain aspartame .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>Escherichia coli , cholera , diarrhea , vaccine</keyword>
</DOC>